399 related articles for article (PubMed ID: 12097537)
21. Varicella vaccine in recipients of hematopoietic-cell transplants.
Kami M; Kim SW; Takaue Y
N Engl J Med; 2002 Nov; 347(20):1624-5; author reply 1624-5. PubMed ID: 12432055
[No Abstract] [Full Text] [Related]
22. Persistence of immunity to live attenuated varicella vaccine in healthy adults.
Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A
Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.
Sasadeusz J; Prince HM; Schwarer A; Szer J; Stork A; Bock HL; Povey M; Nicholson O; Innis BL
Transpl Infect Dis; 2014 Dec; 16(6):1024-31. PubMed ID: 25272081
[TBL] [Abstract][Full Text] [Related]
24. Zoster vaccine: current status and future prospects.
Oxman MN
Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
[TBL] [Abstract][Full Text] [Related]
25. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
[TBL] [Abstract][Full Text] [Related]
26. Risk factors of herpes zoster among children immunized with varicella vaccine: results from a nested case-control study.
Tseng HF; Smith N; Marcy SM; Sy LS; Chao CR; Jacobsen SJ
Pediatr Infect Dis J; 2010 Mar; 29(3):205-8. PubMed ID: 19952977
[TBL] [Abstract][Full Text] [Related]
27. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination.
Jenkins DE; Yasukawa LL; Bergen R; Benike C; Engleman EG; Arvin AM
J Immunol; 1999 Jan; 162(1):560-7. PubMed ID: 9886433
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.
Chaves Tdo S; Lopes MH; de Souza VA; Dos Santos Sde S; Pereira LM; Reis AD; David-Neto E
Pediatr Transplant; 2005 Apr; 9(2):192-6. PubMed ID: 15787792
[TBL] [Abstract][Full Text] [Related]
29. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.
Offidani M; Corvatta L; Olivieri A; Mele A; Brunori M; Montanari M; Rupoli S; Scalari P; Leoni P
Clin Infect Dis; 2001 May; 32(10):1414-22. PubMed ID: 11317241
[TBL] [Abstract][Full Text] [Related]
30. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older.
Levine MJ; Ellison MC; Zerbe GO; Barber D; Chan C; Stinson D; Jones M; Hayward AR
Vaccine; 2000 Jun; 18(25):2915-20. PubMed ID: 10812235
[TBL] [Abstract][Full Text] [Related]
31. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings.
Diaz PS; Au D; Smith S; Amylon M; Link M; Smith S; Arvin AM
Pediatrics; 1991 Feb; 87(2):166-70. PubMed ID: 1846236
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
33. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.
Barbosa CM; Terreri MT; Rosário PO; de Moraes-Pinto MI; Silva CA; Hilário MO
Clin Exp Rheumatol; 2012; 30(5):791-8. PubMed ID: 22935227
[TBL] [Abstract][Full Text] [Related]
34. Perspective on live varicella vaccine.
Gershon AA; Katz SL
J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
[TBL] [Abstract][Full Text] [Related]
35. Modelling the impact of varicella vaccination on varicella and zoster.
Karhunen M; Leino T; Salo H; Davidkin I; Kilpi T; Auranen K
Epidemiol Infect; 2010 Apr; 138(4):469-81. PubMed ID: 19796447
[TBL] [Abstract][Full Text] [Related]
36. Prevention of shingles by varicella zoster virus vaccination.
Holodniy M
Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624
[TBL] [Abstract][Full Text] [Related]
37. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
Goldman GS
Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
[TBL] [Abstract][Full Text] [Related]
38. Outbreak of varicella at a day-care center despite vaccination.
Galil K; Lee B; Strine T; Carraher C; Baughman AL; Eaton M; Montero J; Seward J
N Engl J Med; 2002 Dec; 347(24):1909-15. PubMed ID: 12477940
[TBL] [Abstract][Full Text] [Related]
39. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
40. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
